Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 11/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 9/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.48 |
| ▸ | CCR2 | P41597 | 2/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29456264 | 1.00 | MAPK9 (0.53) | MAPK9MAPK10MAPK8CCR2PTGDR2 | |
| SCHEMBL29456267 | 0.87 | MAPK9 (0.52) | MAPK9MAPK10MAPK8CCR2 | |
| SCHEMBL3782016 | 0.87 | MAPK9 (0.52) | MAPK9MAPK10MAPK8CCR2 | |
| SCHEMBL3783019 | 0.84 | MAPK9 (0.52) | MAPK9MAPK10MAPK8 | |
| SCHEMBL29456293 | 0.84 | MAPK9 (0.52) | MAPK9MAPK10MAPK8 | |
| SCHEMBL29456233 | 0.82 | KDM4E (0.48) | MAPK9MAPK10MAPK8PPARG | |
| SCHEMBL3780636 | 0.82 | KDM4E (0.48) | MAPK9MAPK10MAPK8PPARG | |
| SCHEMBL19495463 | 0.81 | MAPK9 (0.45) | MAPK9MAPK10MAPK8CCR2PPARG | |
| SCHEMBL27990361 | 0.80 | CCR2 (0.50) | CCR2PTGDR2PPARGPPARA | |
| SCHEMBL3783653 | 0.80 | MAPK8 (0.50) | MAPK9MAPK10MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| US-20200277285-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2020-09-03 | — | — | US | disclosed |
| US-20200039972-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2020-02-06 | — | — | US | disclosed |
| US-20190194176-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20180319780-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2018-11-08 | — | — | US | disclosed |
| US-20180037577-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2018-02-08 | — | — | US | disclosed |
| EP-2393806-B1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARM INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9796706-B2 | Inhibitors of Jun N-terminal kinase | IMAGO PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170107209-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2017-04-20 | — | — | US | disclosed |
| US-20150259330-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | IMAGO PHARMACEUTICALS, INC. (US) | 2015-09-17 | — | — | US | disclosed |
| US-9073891-B2 | Inhibitors of Jun N-terminal kinase | IMAGO PHARMACEUTICALS, INC. (US) | 2015-07-07 | — | — | US | disclosed |
| US-8450363-B2 | Inhibitors of Jun N-terminal kinase | ELAN PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20130072494-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARMACEUTICALS, INC. | 2013-03-21 | — | — | US | disclosed |
| EP-2393806-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | Elan Pharmaceuticals Inc. (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100331335-A1 | Inhibitors of Jun N-Terminal Kinase | ELAN PHARMACETICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2010091310-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | ELAN PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039972-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK9 16/4885MAPK10 21/4885MAPK8 24/4885 |
| US-20190194176-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK9 16/4885MAPK10 21/4885MAPK8 24/4885 |
| US-20150259330-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK9 16/4885MAPK10 21/4885MAPK8 24/4885 |
| US-20170107209-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK9 16/4885MAPK10 21/4885MAPK8 24/4885 |
| US-20180037577-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK9 16/4885MAPK10 21/4885MAPK8 24/4885 |
| US-20130072494-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK9 16/4885MAPK10 21/4885MAPK8 24/4885 |
| US-20220081427-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK9 16/4885MAPK10 21/4885MAPK8 24/4885 |
| US-20200277285-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK9 16/4885MAPK10 21/4885MAPK8 24/4885 |
| US-20180319780-A1 | INHIBITORS OF JUN N-TERMINAL KINASE | CHUK, MAPK6, MAPK3 | MAPK9 16/4885MAPK10 21/4885MAPK8 24/4885 |
| US-20100331335-A1 | Inhibitors of Jun N-Terminal Kinase | CHUK, MAPK6, MAPK3 | MAPK9 16/4885MAPK10 21/4885MAPK8 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.